海思科公告称，公司与AirNexis签订独占许可协议，授予其在除中国部分地区外全球开发、生产和商业 化HSK39004的独家权利。AirNexis将支付1.08亿美元首付款（含4000万美元现金及约6800万美元等值股 权）及最高9.55亿美元额外里程碑付款、特许权使用费，若再许可，海思科还有分成。公司董事长王俊 民参与AirNexis 2亿美元投资，出资500万美元占1.4%股权，本次交易构成关联交易，尚需股东会批准。 ...

Core Viewpoint - Fosun Pharma reported a decline in revenue for the first half of the year, but a significant increase in net profit, indicating a potential shift in operational efficiency despite lower sales [1] Financial Performance - The company achieved an operating revenue of 19.514 billion yuan, a year-on-year decrease of 4.63% [1] - The net profit attributable to shareholders was 1.702 billion yuan, reflecting a year-on-year growth of 38.96% [1] Strategic Developments - Fosun Pharma's subsidiary granted Sitala rights for the development, production, and commercialization of FXS6837 and related products in a global scope excluding China (including Hong Kong, Macau, and Taiwan) [1] - As part of this licensing arrangement, Fosun Pharma or its designated affiliates can acquire shares of Sitala valued at 5 million USD at zero cost [1]